Viral vector

A viral vector is a tool used in molecular biology to deliver genetic material into cells. Viruses have a natural ability to infect cells and insert their own genetic code. Scientists have harnessed this capability by modifying viruses to serve as delivery vehicles, or "vectors." The process involves removing the viral genes responsible for causing disease and replication, rendering the virus harmless. In their place, scientists insert a therapeutic gene or other genetic sequence of interest, known as a "transgene." When this modified viral vector is introduced into a patient or a laboratory model, it uses its natural machinery to enter target cells and deliver the therapeutic genetic payload.

Several types of viruses are commonly adapted for use as vectors, each with distinct properties. Adeno-associated viruses (AAVs) are popular because they provoke a relatively mild immune response and do not typically integrate their DNA into the host cell's genome, reducing the risk of disrupting essential host genes. Lentiviruses, a type of retrovirus, are notable for their ability to infect non-dividing cells and integrate the transgene directly into the host's DNA, providing long-term, stable gene expression. Other vectors, such as adenoviruses and herpes simplex viruses, are also used for specific applications, chosen based on factors like target cell type, the size of the genetic payload, and the desired duration of gene expression.

Viral vectors are a cornerstone of modern biotechnology, particularly in the fields of gene therapy and vaccine development. In gene therapy, they represent the most common method for in vivo gene delivery, where the vector is directly administered to the patient to correct a faulty gene or introduce a new function. They are also critical tools in research for creating genetically modified cell lines and animal models to study gene function and disease. Furthermore, viral vector technology has been pivotal in creating vaccines, such as the Oxford-AstraZeneca and Johnson & Johnson COVID-19 vaccines, which use a harmless adenovirus vector to deliver the gene for the SARS-CoV-2 spike protein, prompting the body to mount an immune response.

For patients, the development of safe and effective viral vectors has been transformative, enabling the first wave of approved gene therapies for previously untreatable genetic diseases. Conditions like spinal muscular atrophy (SMA), certain inherited retinal dystrophies, and hemophilia can now be treated with a single administration of a vector-based therapy designed to correct the underlying genetic defect. However, challenges remain. The patient's immune system can sometimes mount a response against the viral vector, reducing its efficacy or causing adverse effects. Scientists are continuously working to refine vector design to improve safety, increase targeting precision, and overcome these immunological hurdles, promising to expand the therapeutic reach of gene therapy to a wider range of diseases.